Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.

<h4>Background and objectives</h4>Natalizumab reduces the relapse rate and magnetic resonance imaging activity in patients with Relapsing-Remitting Multiple Sclerosis (RRMS). So far the influence of natalizumab on cognitive functions and fatigue in MS remains uncertain. The aim of this p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pietro Iaffaldano, Rosa Gemma Viterbo, Damiano Paolicelli, Guglielmo Lucchese, Emilio Portaccio, Benedetta Goretti, Vita Direnzo, Mariangela D'Onghia, Stefano Zoccolella, Maria Pia Amato, Maria Trojano
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/fd8907a15e1b4a6e9664f9498c11f071
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fd8907a15e1b4a6e9664f9498c11f071
record_format	dspace
spelling	oai:doaj.org-article:fd8907a15e1b4a6e9664f9498c11f0712021-11-18T07:20:54ZImpact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.1932-620310.1371/journal.pone.0035843https://doaj.org/article/fd8907a15e1b4a6e9664f9498c11f0712012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22558238/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background and objectives</h4>Natalizumab reduces the relapse rate and magnetic resonance imaging activity in patients with Relapsing-Remitting Multiple Sclerosis (RRMS). So far the influence of natalizumab on cognitive functions and fatigue in MS remains uncertain. The aim of this prospective, open-label, observational study was to evaluate the possible effects of natalizumab on cognition and fatigue measures in RRMS patients treated for up to two years.<h4>Methods</h4>Cognitive performances were examined by the Rao's Brief Repeatable Battery (BRB), the Stroop test (ST) and the Cognitive Impairment Index (CII), every 12 months. Patients who failed in at least 3 tests of the BRB and the ST were classified as cognitively impaired (CI). Fatigue Severity Scale (FSS) was administered every 12 months to assess patient's self-reported fatigue. One hundred and 53 patients completed 1 and 2 year-natalizumab treatment, respectively.<h4>Results</h4>After 1 year of treatment the percentage of CI patients decreased from 29% (29/100) at baseline to 19% (19/100) (p = 0.031) and the mean baseline values of CII (13.52±6.85) and FSS (4.01±1.63) scores were significantly reduced (10.48±7.12, p<0.0001 and 3.61±1.56, p = 0.008). These significant effects were confirmed in the subgroup of patients treated up to two years.<h4>Conclusions</h4>These results demonstrate that a short-term NTZ treatment may significantly improve cognitive performances and fatigue in RRMS patients.Pietro IaffaldanoRosa Gemma ViterboDamiano PaolicelliGuglielmo LuccheseEmilio PortaccioBenedetta GorettiVita DirenzoMariangela D'OnghiaStefano ZoccolellaMaria Pia AmatoMaria TrojanoPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 4, p e35843 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Pietro Iaffaldano Rosa Gemma Viterbo Damiano Paolicelli Guglielmo Lucchese Emilio Portaccio Benedetta Goretti Vita Direnzo Mariangela D'Onghia Stefano Zoccolella Maria Pia Amato Maria Trojano Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
description	<h4>Background and objectives</h4>Natalizumab reduces the relapse rate and magnetic resonance imaging activity in patients with Relapsing-Remitting Multiple Sclerosis (RRMS). So far the influence of natalizumab on cognitive functions and fatigue in MS remains uncertain. The aim of this prospective, open-label, observational study was to evaluate the possible effects of natalizumab on cognition and fatigue measures in RRMS patients treated for up to two years.<h4>Methods</h4>Cognitive performances were examined by the Rao's Brief Repeatable Battery (BRB), the Stroop test (ST) and the Cognitive Impairment Index (CII), every 12 months. Patients who failed in at least 3 tests of the BRB and the ST were classified as cognitively impaired (CI). Fatigue Severity Scale (FSS) was administered every 12 months to assess patient's self-reported fatigue. One hundred and 53 patients completed 1 and 2 year-natalizumab treatment, respectively.<h4>Results</h4>After 1 year of treatment the percentage of CI patients decreased from 29% (29/100) at baseline to 19% (19/100) (p = 0.031) and the mean baseline values of CII (13.52±6.85) and FSS (4.01±1.63) scores were significantly reduced (10.48±7.12, p<0.0001 and 3.61±1.56, p = 0.008). These significant effects were confirmed in the subgroup of patients treated up to two years.<h4>Conclusions</h4>These results demonstrate that a short-term NTZ treatment may significantly improve cognitive performances and fatigue in RRMS patients.
format	article
author	Pietro Iaffaldano Rosa Gemma Viterbo Damiano Paolicelli Guglielmo Lucchese Emilio Portaccio Benedetta Goretti Vita Direnzo Mariangela D'Onghia Stefano Zoccolella Maria Pia Amato Maria Trojano
author_facet	Pietro Iaffaldano Rosa Gemma Viterbo Damiano Paolicelli Guglielmo Lucchese Emilio Portaccio Benedetta Goretti Vita Direnzo Mariangela D'Onghia Stefano Zoccolella Maria Pia Amato Maria Trojano
author_sort	Pietro Iaffaldano
title	Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
title_short	Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
title_full	Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
title_fullStr	Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
title_full_unstemmed	Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
title_sort	impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/fd8907a15e1b4a6e9664f9498c11f071
work_keys_str_mv	AT pietroiaffaldano impactofnatalizumaboncognitiveperformancesandfatigueinrelapsingmultiplesclerosisaprospectiveopenlabeltwoyearsobservationalstudy AT rosagemmaviterbo impactofnatalizumaboncognitiveperformancesandfatigueinrelapsingmultiplesclerosisaprospectiveopenlabeltwoyearsobservationalstudy AT damianopaolicelli impactofnatalizumaboncognitiveperformancesandfatigueinrelapsingmultiplesclerosisaprospectiveopenlabeltwoyearsobservationalstudy AT guglielmolucchese impactofnatalizumaboncognitiveperformancesandfatigueinrelapsingmultiplesclerosisaprospectiveopenlabeltwoyearsobservationalstudy AT emilioportaccio impactofnatalizumaboncognitiveperformancesandfatigueinrelapsingmultiplesclerosisaprospectiveopenlabeltwoyearsobservationalstudy AT benedettagoretti impactofnatalizumaboncognitiveperformancesandfatigueinrelapsingmultiplesclerosisaprospectiveopenlabeltwoyearsobservationalstudy AT vitadirenzo impactofnatalizumaboncognitiveperformancesandfatigueinrelapsingmultiplesclerosisaprospectiveopenlabeltwoyearsobservationalstudy AT mariangeladonghia impactofnatalizumaboncognitiveperformancesandfatigueinrelapsingmultiplesclerosisaprospectiveopenlabeltwoyearsobservationalstudy AT stefanozoccolella impactofnatalizumaboncognitiveperformancesandfatigueinrelapsingmultiplesclerosisaprospectiveopenlabeltwoyearsobservationalstudy AT mariapiaamato impactofnatalizumaboncognitiveperformancesandfatigueinrelapsingmultiplesclerosisaprospectiveopenlabeltwoyearsobservationalstudy AT mariatrojano impactofnatalizumaboncognitiveperformancesandfatigueinrelapsingmultiplesclerosisaprospectiveopenlabeltwoyearsobservationalstudy
_version_	1718423639694508032

Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.

Ejemplares similares